{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:57:15Z","timestamp":1787500635024,"version":"build-2736575974"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We systematically assessed benefits and harms of tocilizumab (TCZ), which is an antibody blocking IL-6 receptors, in hospitalized COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Five electronic databases and two preprint webpages were searched until March 4, 2021. Randomized controlled trials (RCTs) and inverse probability treatment weighting (IPTW) cohorts assessing TCZ effects in hospitalized, COVID-19 adult patients were included. Primary outcomes were all-cause mortality, clinical worsening, clinical improvement, need for mechanical ventilation, and adverse events (AE). Inverse variance random-effects meta-analyses were performed with quality of evidence (QoE) evaluated using GRADE methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine RCTs (n = 7,021) and nine IPTW cohorts (n = 7,796) were included. TCZ significantly reduced all-cause mortality in RCTs (RR 0.89, 95%CI 0.81\u20130.98, p = 0.03; moderate QoE) and non-significantly in cohorts (RR 0.67, 95%CI 0.44\u20131.02, p = 0.08; very low QoE) vs. control (standard of care [SOC] or placebo). TCZ significantly reduced the need for mechanical ventilation (RR 0.80, 95%CI 0.71\u20130.90, p = 0.001; moderate QoE) and length of stay (MD -1.92 days, 95%CI -3.46 to -0.38, p = 0.01; low QoE) vs. control in RCTs. There was no significant difference in clinical improvement or worsening between treatments. AEs, severe AEs, bleeding and thrombotic events were similar between arms in RCTs, but there was higher neutropenia risk with TCZ (very low QoE). Subgroup analyses by disease severity or risk of bias (RoB) were consistent with main analyses. Quality of evidence was moderate to very low in both RCTs and cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In comparison to SOC or placebo, TCZ reduced all-cause mortality in all studies and reduced mechanical ventilation and length of stay in RCTs in hospitalized COVID-19 patients. Other clinical outcomes were not significantly impacted. TCZ did not have effect on AEs, except a significant increased neutropenia risk in RCTs. TCZ has a potential role in the treatment of hospitalized COVID-19 patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0269368","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:48:02Z","timestamp":1654264082000},"page":"e0269368","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-2419","authenticated-orcid":true,"given":"Alejandro","family":"Piscoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Parra del Riego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-1543","authenticated-orcid":true,"given":"Renato","family":"Cerna-Viacava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuani M.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel A.","family":"Escobedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Pasupuleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-4003","authenticated-orcid":true,"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"pone.0269368.ref001","unstructured":"Worldometer. COVID-19 Coronavirus Pandemic. https:\/\/www.worldometers. info\/coronavirus\/. Accessed April 22, 2022."},{"key":"pone.0269368.ref002","article-title":"OpenSAFELY: factors associated with COVID-19 related hospital deaths in the linked electronic health records of 17 million adult NHS patients","author":"The OpenSAFELY Collaborative","year":"2020","journal-title":"medRxiv"},{"key":"pone.0269368.ref003","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"pone.0269368.ref004","doi-asserted-by":"crossref","first-page":"n433","DOI":"10.1136\/bmj.n433","article-title":"Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows","volume":"372","author":"J. Wise","year":"2021","journal-title":"BMJ"},{"key":"pone.0269368.ref005","unstructured":"UpToDate. Uptodate.com. https:\/\/www.uptodate.com\/contents\/tocilizumab-drug-information#F16322788. Published 2021. Accessed March 15, 2021."},{"key":"pone.0269368.ref006","unstructured":"Infectious Disease Society of America. COVID-19 Guideline, Part 1: Treatment and Management. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/. Published April 11, 2020; Updated March 23, 2022. Accessed April 22, 2022."},{"key":"pone.0269368.ref007","unstructured":"Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. https:\/\/app.magicapp.org\/#\/guideline\/L4Q5An\/section\/LrpogE. Published February 18, 2021; Updated April 12, 2022. Accessed April 22, 2022."},{"key":"pone.0269368.ref008","unstructured":"National Institute for Health Care and Excellence (NICE). COVID-19 rapid guideline: Managing COVID-19. https:\/\/www.nice.org.uk\/guidance\/ng191. Published March 23, 2021; Updated April 13, 2022. Accessed April 22, 2022."},{"key":"pone.0269368.ref009","unstructured":"Pan American Health Organization. Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review. https:\/\/iris.paho.org\/handle\/10665.2\/52719. Published February 19 2021; updated April 7, 2022. Accessed April 22, 2022."},{"key":"pone.0269368.ref010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"PC Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"pone.0269368.ref011","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"DF McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"8","key":"pone.0269368.ref012","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pone.0269368.ref013","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"JA Sterne","year":"2016","journal-title":"BMJ"},{"key":"pone.0269368.ref014","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JA Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0269368.ref015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"M J Page","year":"2021","journal-title":"BMJ"},{"issue":"24","key":"pone.0269368.ref016","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"J Hartung","year":"2001","journal-title":"Stat Med"},{"issue":"1","key":"pone.0269368.ref017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to Estimate the between-Study Variance and Its Uncertainty in Meta-Analysis","volume":"7","author":"AA Veroniki","year":"2015","journal-title":"Res Synth Methods"},{"issue":"4","key":"pone.0269368.ref018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"H Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"pone.0269368.ref019","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2020 (developed by Evidence Prime, Inc.). gradepro.org, Accessed March 15, 2021."},{"key":"pone.0269368.ref020","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","author":"for the REMAP-CAP investigators","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0269368.ref021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","volume":"181","author":"O Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"pone.0269368.ref022","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","author":"IO Rosas","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0269368.ref023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia","volume":"384","author":"C Salama","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0269368.ref024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia","volume":"181","author":"C Salvarani","year":"2020","journal-title":"JAMA Internal Medicine"},{"issue":"24","key":"pone.0269368.ref025","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","volume":"383","author":"J Stone","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pone.0269368.ref026","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"VC Veiga","year":"2021","journal-title":"BMJ"},{"issue":"10285","key":"pone.0269368.ref027","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"pone.0269368.ref028","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial","author":"AS Soin","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"pone.0269368.ref029","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","article-title":"Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study","volume":"2","author":"N Biran","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"pone.0269368.ref030","article-title":"Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study","author":"S Chilimuri","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"pone.0269368.ref031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19","volume":"181","author":"S Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"4","key":"pone.0269368.ref032","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/jmv.26674","article-title":"Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety","volume":"93","author":"J Hill","year":"2020","journal-title":"J Med Virol"},{"issue":"2","key":"pone.0269368.ref033","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.cmi.2020.09.021","article-title":"Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study","volume":"27","author":"J Mart\u00ednez-Sanz","year":"2020","journal-title":"Clinical Microbiology and Infection"},{"key":"pone.0269368.ref034","article-title":"Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2020","journal-title":"Clinical Microbiology and Infection"},{"issue":"10","key":"pone.0269368.ref035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/ph13100317","article-title":"Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study","volume":"13","author":"B Rossi","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"2","key":"pone.0269368.ref036","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10875-020-00911-6","article-title":"Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis","volume":"41","author":"M Roumier","year":"2020","journal-title":"J Clin Immunol"},{"key":"pone.0269368.ref037","article-title":"Tocilizumab for Treatment of Mechanically Ventilated Patients with Covid-19","author":"E Somers","year":"2020","journal-title":"Clin Infect Diseases"},{"issue":"6","key":"pone.0269368.ref038","first-page":"1247","article-title":"Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis","volume":"38","author":"O Berardicurti","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"pone.0269368.ref039","article-title":"Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis","author":"TI Hariyanto","year":"2021","journal-title":"Drug Res (Stuttg)"},{"key":"pone.0269368.ref040","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19 [published online ahead of print, 2021 Feb 12]","author":"FA Khan","year":"2021","journal-title":"Thorax"},{"key":"pone.0269368.ref041","doi-asserted-by":"crossref","first-page":"104380","DOI":"10.1016\/j.jcv.2020.104380","article-title":"Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review","volume":"127","author":"SK Alzghari","year":"2020","journal-title":"J Clin Virol"},{"issue":"1","key":"pone.0269368.ref042","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pulmoe.2020.07.003","article-title":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review","volume":"27","author":"A Cortegiani","year":"2021","journal-title":"Pulmonology"},{"issue":"3","key":"pone.0269368.ref043","doi-asserted-by":"crossref","first-page":"106103","DOI":"10.1016\/j.ijantimicag.2020.106103","article-title":"Tocilizumab for severe COVID-19: a systematic review and meta-analysis","volume":"56","author":"H Lan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0269368.ref044","unstructured":"National Institutes of Health. The COVID-19 Treatment Guidelines Panel\u2019s Statement on the Use of Tocilizumab (and Other Interleukin-6 Inhibitors) for the Treatment of COVID-19. https:\/\/www.covid19treatmentguidelines.nih.gov\/statement-on-tocilizumab\/. Last Updated December 16, 2021. Accessed April 22, 2022."},{"key":"pone.0269368.ref045","article-title":"An EUA for Bamlanivimab\u2014A Monoclonal Antibody for COVID-19","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"pone.0269368.ref046","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMe2034495","article-title":"Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection","volume":"384","author":"MS Cohen","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0269368.ref047","doi-asserted-by":"crossref","first-page":"e0243705","DOI":"10.1371\/journal.pone.0243705","article-title":"Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis","volume":"15","author":"A Piscoya","year":"2020","journal-title":"PLoS One"},{"key":"pone.0269368.ref048","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed March 15, 2021."},{"key":"pone.0269368.ref049","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Table 4a. Corticosteroids: Selected Clinical Data. https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/table-4a\/. Accessed March 15, 2021."},{"key":"pone.0269368.ref050","unstructured":"Actemra (tocilizumab) injection label. Accessdata.fda.gov. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125276s092lbl.pdf. Published 2021. Accessed March 15, 2021."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:48:39Z","timestamp":1654264119000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269368"}},"subtitle":[],"editor":[{"given":"Cho","family":"Naing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269368","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]}}}